Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT2...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozawa, Tatsuhiko, Tani, Hideki, Anraku, Yuki, Kita, Shunsuke, Igarashi, Emiko, Saga, Yumiko, Inasaki, Noriko, Kawasuji, Hitoshi, Yamada, Hiroshi, Sasaki, so-Ichiro, Somekawa, Mayu, Sasaki, Jiei, Hayakawa, Yoshihiro, Yamamoto, Yoshihiro, Morinaga, Yoshitomo, Kurosawa, Nobuyuki, Isobe, Masaharu, Fukuhara, Hideo, Maenaka, Katsumi, Hashiguchi, Takao, Kishi, Hiroyuki, Kitajima, Isao, Saito, Shigeru, Niimi, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103358/
https://www.ncbi.nlm.nih.gov/pubmed/35543180
http://dx.doi.org/10.1080/19420862.2022.2072455
Descripción
Sumario:Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

Ejemplares similares